A newly filed lawsuit against Oura Health (Oura) highlights how company-directed share repurchases executed shortly before major financing transactions or anticipated IPOs can create significant D&O risk for late-stage private companies domiciled in Delaware. As companies remain private longer, secondary liquidity transactions involving founders, employees, and former executives seeking to monetize their holdings have become increasingly common. At the same time, these transactions can create fertile ground for litigation when significant valuation-enhancing events emerge shortly after a sale closes.
The lawsuit against Oura, maker of the Oura Ring, and certain of its directors and officers, was filed on May 29, 2026, in the Delaware Court of Chancery. By allegedly repurchasing shares from an existing stockholder at suppressed valuations while in possession of material nonpublic information about the company’s financial trajectory, corporate fiduciaries can face claims that they breached their stringent duties of disclosure and fair dealing under Delaware law. With thousands of late-stage startups eyeing exits, the Oura complaint illustrates how companies risk breaching disclosure obligations and fiduciary duties when they repurchase shareholder stock while concealing impending valuation-moving events.
The following discusses the allegations of the Oura Complaint in more detail, along with potential D&O risks and underwriting takeaways.
The Oura Complaint
The Oura Complaint, filed by former Oura CEO Harpreet Singh Rai in the U.S. District Court for the District of Delaware, alleges that Oura and certain directors and officers orchestrated a scheme to repurchase Rai’s shares at an artificially depressed price by restricting his ability to sell to third parties while concealing material information about an impending financing that significantly increased the company’s valuation. Rai seeks rescission and asserts claims for breach of fiduciary duty, securities fraud, negligent misrepresentation, and related causes of action.
Rai, who served as CEO from 2018 to 2021 and accumulated over three million shares, alleges that after his departure Oura amended its shareholder agreement to give the board broad discretion over share transfers. According to the complaint, the company used this authority to block multiple attempted secondary sales over a two-year period, leaving him effectively unable to obtain liquidity through outside buyers.
The complaint contends that these restrictions were part of a broader effort to control share liquidity and steer Rai toward a company-directed repurchase. In 2024, Oura, acting through a broker, approached Rai about buying back his shares. During negotiations, Rai allegedly inquired about valuation, potential financing, and investor identity, but was told only that the buyer was an existing investor, without disclosure of a pending strategic investment and Series D financing.
Rai ultimately agreed to sell shares at approximately $10 per share and to relinquish associated voting rights. He alleges that after securing these rights, Oura disclosed a financing that valued the company at about $5.5 billion, causing a substantial increase in share value. Rai claims he lost roughly $142 million due to the defendants’ conduct and asserts claims including violations of Section 10(b) and Rule 10b-5.
Discussion
The allegations are particularly noteworthy given Oura’s status as a late-stage private company that has frequently been discussed as a potential IPO candidate, as well as the broader market trend of companies remaining private longer while continuing to raise substantial amounts of capital. As companies stay private for extended periods, secondary liquidity transactions involving founders, employees, former executives, and early investors may become an increasingly important mechanism for monetizing equity holdings. At the same time, these transactions can create litigation risk when significant valuation-enhancing events emerge shortly after a sale is completed.
Although the complaint includes breach of fiduciary duty claims, the lawsuit is first and foremost a securities fraud action. The plaintiff alleges that Oura and certain directors and officers possessed material nonpublic information regarding an impending financing transaction and used that informational advantage in connection with a company-directed repurchase of his shares. Nevertheless, Rai’s effort to characterize a prominent Oura director as a de facto controller appears designed to invoke enhanced scrutiny under Delaware law and potentially expand the scope of liability beyond the federal securities claims themselves.
More broadly, the Oura Complaint could illustrate a recurring risk facing late-stage private companies. As secondary transactions become more common and companies remain private longer, disputes may arise when former shareholders later contend that they sold their shares without access to information that insiders possessed regarding future financings, strategic transactions, acquisitions, IPO plans, or other valuation-enhancing developments. Whether Rai’s allegations against Oura and its directors and officers ultimately succeed remains to be seen, but the claims underscore the litigation risks that can accompany company-sponsored liquidity events occurring shortly before significant corporate developments.
From a D&O insurance perspective, the coverage analysis may be complicated by the mixture of securities law and fiduciary duty allegations. Claims against the individual directors and officers would ordinarily trigger defense coverage under the policy’s Side A and Side B insuring agreements. However, the complaint’s federal securities law allegations raise issues that are frequently addressed differently under private-company D&O policies than under public-company forms.
Unlike public-company D&O policies, which generally provide entity coverage under Side C specifically for securities claims, many private-company D&O policies contain some form of securities exclusion. The scope of those exclusions varies considerably. Some are triggered only after an initial public offering or other specified securities transaction. Others are drafted more broadly and seek to preclude coverage for certain securities-related claims regardless of whether the company is publicly traded. As a result, whether the entity itself would have coverage for the complaint’s securities law allegations would depend heavily on the specific policy language, including the wording of any applicable securities exclusion and any exceptions to that exclusion.
These distinctions illustrate an important underwriting consideration for late-stage private companies. As organizations remain private longer, conduct secondary transactions, and move closer to potential liquidity events, they may face litigation exposures that increasingly resemble those traditionally associated with public companies. Secondary transactions that might have been viewed primarily as corporate finance events can also create securities, fiduciary duty, and governance-related exposures, particularly when they occur close in time to significant valuation events.
Taken together, the Oura Complaint highlights the growing D&O risks associated with private-company liquidity transactions. As venture-backed companies remain private longer, secondary share sales and company-sponsored repurchases are likely to become increasingly common. The Oura lawsuit serves as a reminder that when those transactions occur in proximity to major financings, strategic developments, or anticipated public offerings, disappointed sellers may seek to challenge the transaction by alleging that insiders possessed information that was not shared with them. As a result, these types of claims may become an increasingly important area of exposure for late-stage private companies and their directors and officers.